Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zerbaxa (ceftolozane/tazobactam) for the Treatment of Gram-negative Bacterial Infections

Drug (Brand/Generic)

Zerbaxa (ceftolozane/tazobactam)

Developed by

Merck

Therapy Class

β-lactamase inhibitor

Product Description

Anti-infective

Current Indications

Complicated urinary tract infections (cUTIs) and intra-abdominal infections (cIAIs)

Market Sector

Anti-infectives

Development Status

Approved in the US
Expand

Go Top